- Home
- BDTX vs ANTX Comparison
BDTX vs ANTX Comparison
Compare BDTX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | ANTX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 158.8M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BDTX | ANTX |
|---|---|---|
| Price | $1.80 | $4.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $9.67 | $2.00 |
| AVG Volume (30 Days) | ★ 2.1M | 442.7K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $1.00 |
| 52 Week High | $4.94 | $6.91 |
Technical Indicators
Market Signals| Indicator | BDTX | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 50.97 |
| Support Level | $1.60 | $3.91 |
| Resistance Level | $2.26 | $5.13 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 21.50 | 43.89 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.